24,967 Shares in Medtronic PLC $MDT Acquired by First Bank & Trust

Key Points

• First Bank & Trust acquired 24,967 Medtronic shares worth approximately $1.95 million, while institutional investors collectively own 82.06% of the company.
• Analysts maintain a generally positive outlook, with 18 Buy ratings and nine Holds producing a “Moderate Buy” consensus and an average price target of $98.83. UBS recently upgraded the stock to Buy, citing a potential turnaround.
• Medtronic reported quarterly revenue of $9.81 billion, up 9.9% year over year, and narrowly exceeded EPS estimates; it also raised its quarterly dividend to $0.72 per share, yielding about 3.2%.

First Bank & Trust purchased a new stake in Medtronic PLC (NYSE:MDT - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 24,967 shares of the medical technology company's stock, valued at approximately $1,953,000.

Several other institutional investors also recently made changes to their positions in the stock. Curbstone Financial Management Corp raised its position in shares of Medtronic by 1.8% in the 4th quarter. Curbstone Financial Management Corp now owns 5,594 shares of the medical technology company's stock worth $537,000 after buying an additional 100 shares during the period. New England Capital Financial Advisors LLC boosted its holdings in Medtronic by 7.8% in the fourth quarter. New England Capital Financial Advisors LLC now owns 1,403 shares of the medical technology company's stock valued at $135,000 after acquiring an additional 101 shares during the last quarter. Ipsen Advisor Group LLC grew its position in Medtronic by 1.7% during the fourth quarter. Ipsen Advisor Group LLC now owns 5,952 shares of the medical technology company's stock valued at $572,000 after acquiring an additional 101 shares during the period. Quadrant Capital Group LLC grew its position in Medtronic by 0.3% during the fourth quarter. Quadrant Capital Group LLC now owns 32,477 shares of the medical technology company's stock valued at $3,120,000 after acquiring an additional 101 shares during the period. Finally, Rossby Financial LCC increased its stake in Medtronic by 5.1% during the fourth quarter. Rossby Financial LCC now owns 2,193 shares of the medical technology company's stock worth $211,000 after acquiring an additional 107 shares during the last quarter. 82.06% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on the company. Piper Sandler restated a "neutral" rating on shares of Medtronic in a report on Monday. BTIG Research reiterated a "buy" rating and set a $91.00 target price on shares of Medtronic in a report on Monday, July 13th. Royal Bank Of Canada reissued an "outperform" rating and set a $118.00 target price on shares of Medtronic in a research report on Thursday, June 4th. Sanford C. Bernstein cut their price target on shares of Medtronic from $112.00 to $97.00 and set an "outperform" rating on the stock in a report on Thursday, June 4th. Finally, Mizuho cut their price target on shares of Medtronic from $120.00 to $100.00 and set an "outperform" rating on the stock in a report on Wednesday, June 3rd. Eighteen equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to data from MarketBeat, Medtronic has an average rating of "Moderate Buy" and an average target price of $98.83.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: UBS upgraded Medtronic to Buy from Neutral, describing a “turnaround” underway at the company. The upgrade suggests improving execution and renewed confidence in Medtronic’s ability to return to sustainable growth. Is Medtronic Becoming a Turnaround Story?
• Positive Sentiment: Medtronic is being promoted as an undervalued dividend-growth company, which may attract income-focused investors if the market begins to recognize potential for operational improvement and valuation expansion. Medtronic: Buy This Undervalued Dividend Aristocrat
• Positive Sentiment: Medtronic’s collaboration with Orchestra BioMed is progressing: the BACKBEAT pivotal trial remains on track to reach its enrollment target by the end of the third quarter of 2026, with primary data expected in the second quarter of 2027. Successful results could support future device-related growth. Orchestra BioMed Reports Second Quarter 2026 Results
• Neutral Sentiment: Recent coverage highlights Medtronic’s appeal relative to Johnson & Johnson and Abbott, but portrays the company more as a turnaround and valuation opportunity than a consistent high-growth story. Investors may continue to favor peers with stronger near-term organic growth. Johnson & Johnson vs. Medtronic Abbott vs. Medtronic

Insider Buying and Selling

In related news, EVP Harry Skip Kiil sold 4,189 shares of the business's stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the transaction, the executive vice president directly owned 37,227 shares of the company's stock, valued at approximately $2,994,539.88. The trade was a 10.11% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.26% of the company's stock.

Medtronic Stock Up 2.5%

Shares of NYSE MDT opened at $89.31 on Tuesday. The stock has a fifty day moving average price of $82.25 and a 200 day moving average price of $86.55. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a market cap of $114.32 billion, a P/E ratio of 23.94, a P/E/G ratio of 2.34 and a beta of 0.55.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 EPS for the quarter, topping analysts' consensus estimates of $1.54 by $0.01. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The company had revenue of $9.81 billion for the quarter, compared to analysts' expectations of $9.62 billion. During the same quarter in the previous year, the firm posted $1.62 earnings per share. The firm's quarterly revenue was up 9.9% on a year-over-year basis. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Research analysts anticipate that Medtronic PLC will post 5.94 EPS for the current fiscal year.

Medtronic Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, July 17th. Investors of record on Friday, June 26th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 3.2%. The ex-dividend date was Friday, June 26th. This is an increase from Medtronic's previous quarterly dividend of $0.71. Medtronic's dividend payout ratio (DPR) is 77.21%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source